Skip to content
Screener

NovoCure NVCR Total Cost of Revenue

Total Cost of Revenue at other companies

Boston Scientific logo
Boston ScientificBSX
$1.59B-2.6%
Medtronic logo
MedtronicMDT
$3.4B+8.0%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$43.6M-10.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$2.21M+91.9%
AngioDynamics logo
AngioDynamicsANGO
$39.83M+5.0%
CTO
Citius Oncology, Inc.CTOR
$328.88K

Segments

By product

See full
Shipping and Handling$4.26M+30.8%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025Year ended December 31, 2025
Net revenues$183,584$158,805$357,639$313,799$655,353
Cost of revenues41,10641,47280,03579,993166,879
Gross profit142,478117,333277,604233,806488,474
Operating costs and expenses:
Research, development and clinical studies51,44855,833109,784109,610224,544
Sales and marketing61,68457,066120,041112,858240,064
General and administrative39,90843,955125,76188,724177,666
Total operating costs and expenses153,040156,854355,586311,192642,274

Item 1. Financial Statements

FAQ

What is NovoCure's total cost of revenue?
NovoCure (NVCR) reported total cost of revenue of $41.11M in Q2 2026.
How has NovoCure's total cost of revenue changed year-over-year?
NovoCure's total cost of revenue decreased by 0.9% year-over-year, from $41.47M to $41.11M.
What is the long-term trend for NovoCure's total cost of revenue?
Over 4 years (2021 to 2025), NovoCure's total cost of revenue has grown at a 9.8% compound annual growth rate (CAGR), from $114.88M to $166.88M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about NovoCure's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude